IKSUDA
LIVE

Serial Number

79240120

Owner

IKSUDA THERAPEUTICS LIMITED

Attorney

William S. Fultz

Filing Date

May 17, 2018

Add to watchlist:

No watchlists yet
View on USPTO

IKSUDA Trademark

Serial Number: 79240120 • Registration: 5766418

IKSUDA is a trademark filed by IKSUDA THERAPEUTICS LIMITED on May 17, 2018. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 16 (Paper Goods). The application is currently registered and active.

Owner Contact Info

IKSUDA THERAPEUTICS LIMITED (9 trademarks)

The Biosphere, Draymans Way,

Entity Type: 11

Trademark Details

Filing Date

May 17, 2018

Registration Date

June 4, 2019

Published for Opposition

March 19, 2019

Goods & Services

Pharmaceuticals for the treatment of cancer; pharmaceuticals and medical preparations for the treatment of inflammatory diseases; vaccines for the treatment of cancer; vaccines for the treatment of gene and cell therapy; vaccines for the treatment of inflammatory diseases; pharmaceutical and medical preparations for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical products for the prevention and treatment of cancer; biopharmaceuticals for the treatment of cancer; biopharmaceuticals for the treatment of inflammatory diseases; hormones and analogues for medical purposes; biopharmaceutical and pharmaceutical gene and cell therapy products, namely, therapeutic pharmaceuticals for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders

Scientific and technological services, namely, scientific research, design, analysis and testing in the field of biotherapeutics for treating cancer; medical and pharmaceutical research services; research and development of vaccines and medicines; industrial analysis and research services, namely, synthetic chemistry, bioconjugation, and scientific analysis of antibody-drug conjugates and biotherapeutics; scientific research; pharmaceutical research; biological research; biotechnology testing services, namely, synthetic chemistry, recombinant protein production, bioconjugation, testing, analysis, and evaluation of antibody-drug conjugates and biotherapeutics to assure compliance with industry standards; medical research services in the field of cancer; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; conducting clinical trials for others; design of clinical trials for others in the field of vaccines and gene therapy; scientific research for medical purposes; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; information, advisory and consultancy services relating to the aforesaid

Paper; cardboard; printed matter, namely, paper signs, books, manuals, business cards, newsletters, informational cards, posters, brochures, letters, certificates in the field of biotherapeutics; bookbinding material; photographs; stationery; printed instructional, educational, and teaching materials in the field of medicine; publications, namely, books, hand-outs, workbooks, posters, research articles in the fields of science, medicine and biotherapeutics; publications for the medical profession, namely, magazines, newsletters, research articles in the field of medicine

[ Chemical products for use in industry and science; reagents for use in scientific apparatus for chemical or biological analysis; reagents for medical research; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; chemical preparations for scientific and industrial processes, namely, vinyl pyridine-based linkers, vinyl pyridine derivatives, and difluorosialic acid; enzymes for industrial use; cell culture media for use in scientific research; active chemical ingredients for use in the manufacture of anti-cancer drugs ]

Filing History

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jun 8, 2026 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Oct 8, 2025 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
Oct 8, 2025 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 6, 2025 APRE
TEAS SECTION 71 RECEIVED
Jun 27, 2025 ES71
NEW REPRESENTATIVE AT IB RECEIVED
Nov 29, 2024 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 4, 2024 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 12, 2021 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Jan 22, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 18, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 12, 2019 FICS
FINAL DISPOSITION PROCESSED
Sep 12, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 4, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 4, 2019 R.PR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 26, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 26, 2019 REAP
PUBLISHED FOR OPPOSITION
Mar 19, 2019 PUBO
NOTIFICATION PROCESSED BY IB
Mar 16, 2019 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 27, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 27, 2019 OP2R
NOTICE OF PUBLICATION
Feb 27, 2019 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 13, 2019 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 11, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 7, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 7, 2019 CRFA
ASSIGNED TO LIE
Feb 4, 2019 ALIE
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 1, 2019 ADCH
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 31, 2019 TROA
REFUSAL PROCESSED BY IB
Oct 13, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 24, 2018 RFCS
REFUSAL PROCESSED BY MPU
Sep 24, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 18, 2018 RFCR
APPLICATION FILING RECEIPT MAILED
Sep 18, 2018 MAFR
NON-FINAL ACTION WRITTEN
Sep 17, 2018 CNRT
ASSIGNED TO EXAMINER
Sep 13, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 13, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 6, 2018 REPR